Related Experiment Video

Updated: Jul 28, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Progress in active specific immunotherapy of prostate cancer

B A Tjoa1, G P Murphy

  • 1Northwest Biotherapeutics, Inc., Seattle, Washington 98125, USA. benhenry@nwbio.org

Seminars in Surgical Oncology
|January 5, 2000
PubMed

Insights

Current treatments for metastatic prostate cancer lack curative potential, prompting research into novel immunotherapies. This review explores active specific immunotherapeutic strategies, including various vaccine approaches, to enhance the immune response against prostate cancer.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Therapeutics

Background:

  • Metastatic prostate cancer treatments currently lack significant curative potential.
  • Novel therapeutic strategies are urgently needed for advanced prostate cancer.
  • Cancer immunotherapy harnesses the patient's immune system to combat cancer cells.

Purpose of the Study:

  • To review advancements in active specific immunotherapy for metastatic prostate cancer.
  • To discuss potential alternative treatment methods utilizing immune system components.
  • To explore strategies for augmenting anti-prostate cancer immune responses.

Main Methods:

  • Review of current literature on active specific immunotherapeutic approaches.
  • Discussion of various methods to enhance immune response against prostate cancer.
  • Exploration of systemic cytokine adjuvant therapy, gene-transduced tumor vaccines, non-antigen specific immunization, DNA/peptide vaccines, and dendritic cell-based vaccines.

Main Results:

  • Active specific immunotherapy presents a promising avenue for metastatic prostate cancer treatment.
  • Multiple strategies exist to stimulate an immune response against prostate cancer.
  • Vaccine-based approaches, including dendritic cell vaccines, show potential.

Conclusions:

  • Active specific immunotherapy offers a potential alternative to existing treatments for metastatic prostate cancer.
  • Further research and development in these immunotherapeutic strategies are warranted.
  • Augmenting the immune response is a key focus for future prostate cancer therapies.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...